These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15678666)

  • 1. [An experimental substantiation for using the "Semax" neuroprotector in the treatment of optic-nerve diseases].
    Sheremet NL; Polunin GS; Ovchinnikov AN; Kamenskiĭ AA; Levitskaia NG; Andreeva LA; Alfeeva LIu; Nagaev IIu
    Vestn Oftalmol; 2004; 120(6):25-7. PubMed ID: 15678666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease].
    Polunin GS; Nurieva SM; Baiandin DL; Sheremet NL; Andreeva LA
    Vestn Oftalmol; 2000; 116(1):15-8. PubMed ID: 10741256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].
    Kurysheva NI; Shpak AA; Ioĭleva EE; Galanter LI; Nagornova ND; Shubina NIu; Shlyshalova NN
    Vestn Oftalmol; 2001; 117(4):5-8. PubMed ID: 11569188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].
    Shevchenko KV; Nagaev IIu; Alfeeva LIu; Andreeva LA; Kamenskiĭ AA; Levitskaia NG; Shevchenko VP; Grivennikov IA; Miasoedov NF
    Bioorg Khim; 2006; 32(1):64-70. PubMed ID: 16523722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The comparison of neuroprotective action of antibodies to glutamate and drug preparation semax in the focal ischemic damage of the brain prefrontal cortex of rats].
    Romanova GA; Shakova FM; Davydova TV
    Patol Fiziol Eksp Ter; 2012; (3):62-7. PubMed ID: 23072114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex].
    Agapova TIu; Agniullin IaV; Silachev DN; Shadrina MI; Slominskiĭ PA; Shram SI; Limborskaia SA; Miasoedov NF
    Mol Gen Mikrobiol Virusol; 2008; (3):28-32. PubMed ID: 18756821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of semax on heart rate variability in various daytime periods].
    Arushanian EB; Popov AV
    Eksp Klin Farmakol; 2009; 72(2):32-4. PubMed ID: 19441725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroprotective effects of semax in MPTP-induced disturbances of brain dopamine system].
    Levitskaia NG; Sebentsova EA; Andreeva LA; Alfeeva LIu; Kamenskiĭ AA; Miasoedov NF
    Ross Fiziol Zh Im I M Sechenova; 2002 Nov; 88(11):1369-77. PubMed ID: 12587264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex.
    Romanova GA; Silachev DN; Shakova FM; Kvashennikova YN; Viktorov IV; Shram SI; Myasoedov NF
    Bull Exp Biol Med; 2006 Dec; 142(6):663-6. PubMed ID: 17603664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.
    Dolotov OV; Karpenko EA; Seredenina TS; Inozemtseva LS; Levitskaya NG; Zolotarev YA; Kamensky AA; Grivennikov IA; Engele J; Myasoedov NF
    J Neurochem; 2006 Apr; 97 Suppl 1():82-6. PubMed ID: 16635254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of semax against the background of dopaminergic receptor blockade with haloperidol.
    Sebentsova EA; Levitskaya NG; Andreeva LA; Alfeeva LY; Kamenskii AA; Myasoedov NF
    Bull Exp Biol Med; 2006 Feb; 141(2):170-4. PubMed ID: 16984088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of semax and the C-terminal peptide PGP on expression of growth factor genes and receptors in rats under conditions of experimental cerebral ischemia.
    Dmitrieva VG; Dergunova LV; Povarova OV; Skvortsova VI; Limborskaya SA; Myasoedov NF
    Dokl Biochem Biophys; 2008; 422():261-4. PubMed ID: 19024553
    [No Abstract]   [Full Text] [Related]  

  • 13. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax].
    Serdiuk AV; Levitskiĭ GN; Miasoedov NF; Skvortsova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(4):29-39. PubMed ID: 18379501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-lasting behavioral effects of chronic neonatal treatment with ACTH (4-10) analogue semax in white rat pups].
    Sebentsova EA; Denisenko AV; Levitskaia NG; Andreeva LA; Kamenskiĭ AA; Miasoedov NF
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2005; 55(2):213-20. PubMed ID: 15895862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy].
    Nazarova GA; Konchugova TV; Iurova OV; Turova EA; Rassulova MA; Sichinava NV; Morozova NE
    Vopr Kurortol Fizioter Lech Fiz Kult; 2013; (5):29-32. PubMed ID: 24437205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between the therapeutic effect of the peptide preparation semax and the severity of brain ischemia].
    Khugaeva VK; Aleksandrin VV
    Biull Eksp Biol Med; 1997 Jul; 124(7):39-42. PubMed ID: 9303728
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of behaviorally active ACTH (4-10) analogue - Semax on rat basal forebrain cholinergic neurons.
    Grivennikov IA; Dolotov OV; Zolotarev YA; Andreeva LA; Myasoedov NF; Leacher L; Black IB; Dreyfus CF
    Restor Neurol Neurosci; 2008; 26(1):35-43. PubMed ID: 18431004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of the efficacy of semax in global cerebral ischemia in vivo].
    Iakovleva EV; Kuzenkov VS; Fedorov VN; Skvortsova VI; Koshelev VB; Gusev EI; Ashmarin IP
    Biull Eksp Biol Med; 1999 Aug; 127(8):172-4. PubMed ID: 11188738
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of semax at a follow-up of patients with posthypoxic encephalopathy].
    Alekseeva GV; Bottaev NA; Goroshkova VV
    Anesteziol Reanimatol; 1999; (1):40-3. PubMed ID: 10199046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)].
    Asmarin IP; Nezavibat'ko VN; Miasoedov NF; Kamenskiĭ AA; Grivennikov IA; Ponomareva-Stepnaia MA; Andreeva LA; Kaplan AIa; Koshelev VB; Riasina TV
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1997; 47(2):420-30. PubMed ID: 9173745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.